According to Zacks, “Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States. “
Other equities analysts also recently issued reports about the stock. ValuEngine downgraded shares of Eidos Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, December 17th. JPMorgan Chase & Co. downgraded shares of Eidos Therapeutics from an “overweight” rating to a “neutral” rating and set a $29.00 price objective for the company. in a research note on Wednesday, January 23rd. Finally, BMO Capital Markets initiated coverage on shares of Eidos Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $28.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $27.00.
Eidos Therapeutics (NASDAQ:EIDX) last issued its quarterly earnings data on Monday, April 15th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.01). As a group, analysts expect that Eidos Therapeutics will post -1.99 earnings per share for the current fiscal year.
In related news, insider Jonathan C. Fox sold 5,000 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $23.11, for a total value of $115,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christine Siu sold 11,913 shares of the stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $19.66, for a total transaction of $234,209.58. The disclosure for this sale can be found here.
A number of hedge funds have recently added to or reduced their stakes in EIDX. Aisling Capital Management LP bought a new position in Eidos Therapeutics in the fourth quarter worth about $15,461,000. BlackRock Inc. raised its stake in Eidos Therapeutics by 385.1% in the third quarter. BlackRock Inc. now owns 727,698 shares of the company’s stock worth $7,264,000 after buying an additional 577,698 shares in the last quarter. Victory Capital Management Inc. bought a new position in Eidos Therapeutics in the fourth quarter worth about $2,835,000. Hillhouse Capital Advisors Ltd. bought a new position in Eidos Therapeutics in the fourth quarter worth about $2,458,000. Finally, Vanguard Group Inc raised its stake in Eidos Therapeutics by 297.3% in the third quarter. Vanguard Group Inc now owns 198,673 shares of the company’s stock worth $1,983,000 after buying an additional 148,673 shares in the last quarter. 30.15% of the stock is owned by institutional investors.
Eidos Therapeutics Company Profile
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Read More: What is a put option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.